Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTEIPA
2023-504755-26-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Intercommunal de Créteil
- Start
- Feb 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in bronchiectasis and Pseudomonal infection comparing Ciprofloxacin + ceftazidime arm with Ciprofloxacin + nebulized colistimethate sodium arm (2 arms). Primary endpoint: Pseudomonas aeruginosa eradication rate at 6 months. Planned start Feb 2024; status: authorised.
02
Drugs
ciprofloxacinceftazidimecolistimethate sodium
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on 2023-504755-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504755-26-00.